Victims of a scandal involving the administration of a drug associated with cancer risk to pregnant women are scheduled to have a meeting with Wes Streeting today. The Health Secretary will engage with affected families regarding the “silent scandal” of diethylstilbestrol (DES) prescribed to pregnant women from the 1940s to the 1970s. Approximately 500 women who were exposed to the drug, along with their descendants, have reported various health issues such as infertility, reproductive abnormalities, and an elevated likelihood of breast, pancreatic, and cervical cancers.
Susie Martin, a resident of Manchester, whose mother took DES, has undergone numerous surgical procedures, totaling between 20 to 30 operations. The 55-year-old emphasized the immense impact of the harmful drug on numerous lives, including her own, expressing the unbearable physical and emotional suffering endured. She highlighted the fear of potential future surgeries or cancer development, echoing the sentiments of many others affected. Martin underscored the importance of addressing this long-standing issue and expressed gratitude for the recent attention brought to their plight.
Referred to as a “hidden thalidomide,” DES has been linked to generational harm, impacting subsequent family members. Initially used as a synthetic form of the female hormone estrogen to prevent miscarriages, premature labor, and other medical conditions, DES was later associated with serious health risks. DES Justice UK (DJUK) revealed that around 300,000 women received DES prescriptions over nearly four decades. Despite being linked to cervical and vaginal cancer in 1971, the drug continued to be administered in Europe until 1978, raising concerns about its prolonged usage.
Wes Streeting, acknowledging the government’s past errors in handling the DES scandal, expressed apologies to the victims and encouraged potentially affected individuals to consult with their general practitioners. While compensation schemes exist for DES victims in some countries, the UK lacks a similar program. Clare Fletcher, representing DES Justice UK, emphasized the need for accountability and transparency through a statutory public inquiry to uncover the truth behind the widespread prescription of DES despite known risks.
The Department of Health and Social Care acknowledged the distressing experiences of individuals affected by DES and recognized the ongoing repercussions across generations. Efforts are being made to explore additional support measures for impacted women and families. The NHS has been alerted to the risks associated with DES, ensuring healthcare professionals are equipped with the necessary information to address potential exposure cases promptly.
